Patent application number | Description | Published |
20080227717 | Potent compstatin analogs - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. | 09-18-2008 |
20100222550 | Compstatin analogs with improved activity - Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed. | 09-02-2010 |
20100311086 | Complement-Mediated Thrombophilic Assay - A method for assessing the presence of an acquired thrombophilia disorder in a patient exhibiting hypercoagulation is disclosed. | 12-09-2010 |
20110008343 | Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation - Methods for reducing rejection of pancreatic islet cells transplanted into a subject are disclosed. The methods involve transplanting pancreatic islet cells into a subject in the presence of a complement inhibitor, alone or combined with dextran sulfate. | 01-13-2011 |
20110044983 | COMPLEMENT INHIBITORS AS THERAPEUTIC AGENTS FOR TREATMENT OF CANCER - Methods for treating, preventing or delaying onset of tumor formation and other forms of cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumor microenvironment. | 02-24-2011 |
20110046075 | Secreted Staphylococcus Aureus Proteins And Peptides For Use In Inhibiting Activation Of The Complement System - Compounds comprising peptides and peptide analogs capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds mimic the structure and activity of secreted | 02-24-2011 |
20110060127 | Structure Of Compstatin-C3 Complex And Use For Rational Drug Design - The structure of C3c in complex with the complement inhibitor, compstatin, and use of this information for rational design or identification of complement-inhibiting drugs are disclosed. | 03-10-2011 |
20110142837 | Method Of Treating Acute Respiratory Distress Syndrome - Methods for treating and/or alleviating acute respiratory distress syndrome in an individual diagnosed with or at risk of developing acute respiratory distress syndrome are disclosed. The methods comprise administering a therapeutically effective amount of a complement inhibitor or a TNF-alpha inhibitor to the individual, wherein the complement inhibitor or the TNF-alpha inhibitor reduces or prevents tissue factor production in alveolar neutrophils, thereby treating the ARDS, or delaying or preventing onset of ARDS. | 06-16-2011 |
20120004393 | Potent Compstatin Analogs - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. | 01-05-2012 |
20130344082 | METHODS OF TREATING OR PREVENTING PERIODONTITIS AND DISEASES ASSOCIATED WITH PERIODONTITIS - The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis. | 12-26-2013 |
Patent application number | Description | Published |
20110256136 | Complement Inhibitors For Treatment Of Injury From Intracerebral Hemorrhage - Methods for treating or ameliorating the damage resulting from intracerebral hemorrhage are disclosed. The methods involve administration of a complement inhibitor to inhibit C3 | 10-20-2011 |
20110269113 | METHOD OF INHIBITING BIOMATERIAL-INDUCED PROCOAGULANT ACTIVITY USING COMPLEMENT INHIBITORS - Methods for reducing or eliminating biomaterial-induced procoagulant activity in blood subjected to extracorporeal treatment that exposes the blood to the biomaterial are disclosed. The methods involve treatment of the blood, or the extracorporeal biomaterial, or both, with a complement inhibitor to inhibit C5a/C5aR-mediated tissue factor formation in the blood. | 11-03-2011 |
20110275150 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY - Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed. | 11-10-2011 |
20120178694 | Modified Compstatin With Peptide Backbone And C-Terminal Modifications - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13. | 07-12-2012 |
20130034568 | METHODS OF TREATING OR PREVENTING PERIODONTITIS AND DISEASES ASSOCIATED WITH PERIODONTITIS - The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis. | 02-07-2013 |
20130344592 | Factor H Binding Peptides and Uses Thereof - Factor H-binding peptides that binds to a region of factor H that does not impede the complement-inhibitory activity of factor H are disclosed. When immobilized onto the surface of a biomaterial, these peptides recruit factor H, resulting in a substantial inhibition of biomaterial-induced complement activation in a biological substance exposed to the biomaterial. | 12-26-2013 |
20140113874 | Modified Compstatin With Improved Stability And Binding Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs in which the disulfide bond between C2 and C12 is modified via a thioether bond to form a cystathionine. | 04-24-2014 |
20140219999 | TREATMENT OF COLON CANCER USING COMPLEMENT INHIBITORS - Methods for treating, preventing or delaying onset of polyp formation and subsequent colon cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumorigenic or pre-tumorigenic tissue. | 08-07-2014 |